Compare

Carl Zeiss Meditec/€AFX

1D1W1M3M6MYTD1Y5YMAX

About Carl Zeiss Meditec

Carl Zeiss Meditec AG, publicly traded under the ticker symbol AFX, specializes in the healthcare technology sector. Founded in 2002 as a spin-off from Carl Zeiss AG, it provides comprehensive medical solutions for ophthalmology and microsurgery. Operating globally, the company combines its expertise in optics, electronics, and precision engineering to offer innovative products that enhance patient care and clinical outcomes.
Ticker
€AFX
Sector
Health
Primary listing
XETRA
Employees
5,798
Headquarters
Jena, Germany
Website
www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir

AFX Metrics

BasicAdvanced
€3.1B
24.99
€1.39
1.35
€0.55
1.58%

What the Analysts think about AFX

Analyst ratings (Buy, Hold, Sell) for Carl Zeiss Meditec stock.
Analyst projections of the future price of Carl Zeiss Meditec stock.

Bulls say / Bears say

ProfitUp targets more than €200 million of annual earnings improvement by 2028/29, with over €160 million expected to remain after higher infrastructure costs. If delivered, this could support a recovery in the adjusted EBITA margin to at least about 15%. (Carl Zeiss Meditec)
Nine-month revenue was flat on a currency-adjusted basis, and management reported a solid order backlog. Microsurgery revenue rose 7.1% on that basis, helped by strong deliveries of neurosurgical microscopes, providing some support beyond the weaker ophthalmology business. (Carl Zeiss Meditec)
ZEISS says more than 15 million eyes have now been treated with SMILE and SMILE pro, with over 3,000 surgeons using the technology across more than 80 countries. That growing use suggests its refractive-surgery products have a substantial installed base to build on. (Carl Zeiss Meditec)
Profitability has fallen sharply: nine-month adjusted EBITA dropped to €124.5 million from €177 million, and the adjusted margin narrowed to 8% from 11.1%. This leaves the company with a significant recovery to achieve even before it reaches its medium-term margin target. (Carl Zeiss Meditec)
Ophthalmology remains under pressure from the withdrawal of a bifocal lens from China’s procurement tender, weaker refractive-laser sales and softer equipment investment in APAC. The company expects full-year revenue of only about €2.15–2.20 billion and an adjusted EBITA margin of 8%–10%, below last year’s 11.6% margin. (Carl Zeiss Meditec)
Procurement changes and competition could make the recovery structurally harder: UBS sees possible price declines in Chinese equipment and stronger rivals in DORC and diagnostics. It also forecasts 2029 margins well below management’s target, raising the risk that the savings and recovery plan will fall short. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.

AFX Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

AFX Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing AFX

AllEURUSDGBP
Funds
Fund name
Fund size
€AFX weighting
iShares TecDAX€EXS2
€645M1.00%
iShares Ageing Population$AGED
$953M0.13%
iShares Ageing Population£AGES
$953M0.13%
iShares Ageing Population€AGED
$903M0.13%
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.08%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.